CCCC vs CELU

C4 Therapeutics, Inc. vs Celularity Inc. — Valuation Comparison 2026

CCCC

Biotechnology
C4 Therapeutics, Inc.
Quality
5.3
out of 10
Value Trap
24
SAFE
Price
$3.66
Last close
Models
9/13
Active
VS

CELU

Biotechnology
Celularity Inc.
Quality
4.9
out of 10
Value Trap
36
LOW
Price
$0.99
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CCCC Fair ValueCCCC Upside CELU Fair ValueCELU Upside
Bayesian DCF Intrinsic $0.78 -78.6%
Earnings Power Value Intrinsic $3.41 +256.8%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.26 -91.2% $3.23 +225.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $3.80 +3.9% $4.08 +311.8%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CCCC vs CELU — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CCCC vs CELU — Which Stock Is More Undervalued?

CCCC scores higher with a 5.3/10 quality rating vs CELU's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing C4 Therapeutics, Inc. (CCCC) and Celularity Inc. (CELU) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CCCC currently trades at $3.66 with a QOC of 5.3/10, while CELU trades at $0.99 with a QOC of 4.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).